EE200300331A - Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin - Google Patents

Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin

Info

Publication number
EE200300331A
EE200300331A EEP200300331A EE200300331A EE200300331A EE 200300331 A EE200300331 A EE 200300331A EE P200300331 A EEP200300331 A EE P200300331A EE 200300331 A EE200300331 A EE 200300331A EE 200300331 A EE200300331 A EE 200300331A
Authority
EE
Estonia
Prior art keywords
recombinant
vaccine
eukaryotic cell
mva virus
nef protein
Prior art date
Application number
EEP200300331A
Other languages
English (en)
Other versions
EE05138B1 (et
Inventor
Sutter Gerd
Ohlmann Marion
Erfle Volker
Original Assignee
GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH filed Critical GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Publication of EE200300331A publication Critical patent/EE200300331A/et
Publication of EE05138B1 publication Critical patent/EE05138B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200300331A 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin EE05138B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK78295 1995-07-04
PCT/EP1996/002926 WO1997002355A1 (en) 1995-07-04 1996-07-03 Recombinant mva virus, and the use thereof

Publications (2)

Publication Number Publication Date
EE200300331A true EE200300331A (et) 2003-10-15
EE05138B1 EE05138B1 (et) 2009-02-16

Family

ID=8097499

Family Applications (3)

Application Number Title Priority Date Filing Date
EE9700344A EE04199B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine
EEP200300331A EE05138B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EE9700344A EE04199B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Country Status (26)

Country Link
US (6) US6440422B1 (et)
EP (3) EP1312678B1 (et)
JP (3) JP4312260B2 (et)
KR (1) KR19990028617A (et)
CN (3) CN1782071A (et)
AT (3) ATE304057T1 (et)
AU (1) AU721735B2 (et)
BR (1) BR9609303B8 (et)
CA (3) CA2608864C (et)
CZ (1) CZ292460B6 (et)
DE (3) DE69635173T2 (et)
DK (3) DK0836648T3 (et)
EE (3) EE04199B1 (et)
ES (3) ES2199294T3 (et)
HU (2) HU229261B1 (et)
IL (5) IL122120A (et)
MX (1) MX9800025A (et)
NO (1) NO322476B1 (et)
NZ (1) NZ313597A (et)
PL (1) PL186857B1 (et)
PT (1) PT836648E (et)
RU (1) RU2198217C2 (et)
SI (3) SI1312678T1 (et)
TW (2) TWI245075B (et)
UA (3) UA68327C2 (et)
WO (1) WO1997002355A1 (et)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
MY119381A (en) * 1996-12-24 2005-05-31 Gsf Forschungszentrum Umwelt Recombinant mva virus, and the use thereof
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) * 1998-10-22 2000-04-28 Transgene Sa Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
ATE412762T1 (de) 1999-05-28 2008-11-15 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
CN1291012C (zh) 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
RU2217162C2 (ru) * 2000-04-10 2003-11-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Вакцина против вирусных инфекций
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
AU2002211654A1 (en) * 2000-10-10 2002-04-22 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
JP5322252B2 (ja) 2001-12-20 2013-10-23 バヴァリアン・ノルディック・アクティーゼルスカブ 感染細胞からのポックスウイルスの採取および精製法
NZ536592A (en) 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
BR0310020A (pt) * 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
WO2004048582A2 (en) 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
DE602004015418D1 (de) * 2003-02-18 2008-09-11 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
EP1601333B1 (en) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
DE602004018284D1 (de) 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1845164B1 (en) * 2003-11-24 2010-06-16 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus ankara
US7638132B2 (en) 2003-12-05 2009-12-29 National University Corporation Hokkaido University Highly safe smallpox vaccine virus and vaccinia virus vector
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
CA2670804A1 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
HUE030533T2 (hu) * 2006-06-20 2017-05-29 Transgene Sa Eljárás poxvírusok és poxvírus-készítmények elõállítására
WO2008076157A2 (en) * 2006-09-08 2008-06-26 Duke University Modified vaccinia ankara virus vaccine
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
DK2073837T3 (da) 2006-10-06 2014-09-29 Bavarian Nordic Inc Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
CA2676129A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
EP2208737B1 (en) 2007-05-03 2017-07-05 Lysomab GmbH Complement factor H-derived short consensus repeat-antibody constructs
US8003363B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
JP2010526546A (ja) * 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
US20100285050A1 (en) * 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
CN102257134B (zh) 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
TWI555531B (zh) 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
JP5798124B2 (ja) * 2009-11-20 2015-10-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2739293B1 (en) * 2011-08-05 2020-06-10 SillaJen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
CN104039968B (zh) * 2011-09-26 2018-10-26 赛拉福柯蒂斯公司 非b亚型gag蛋白在慢病毒包装中的应用
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CN104640564B (zh) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 分枝杆菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
US11701418B2 (en) 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
EP3402802B1 (en) * 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
CN109152827B (zh) * 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
AR109528A1 (es) 2016-09-15 2018-12-19 Janssen Vaccines & Prevention Bv Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
AU2020366460A1 (en) * 2019-10-16 2022-03-24 Kalivir Immunotherapeutics, Inc. Producer viruses for generation of retroviruses in SITU
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CA3197371A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
EP4680277A1 (en) 2023-03-17 2026-01-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) * 1988-11-11 1990-05-30 中国科学院上海生物化学研究所 乙肝疫苗的制备方法及其制品
JPH03271233A (ja) 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
EP0613378A1 (en) 1991-10-28 1994-09-07 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
PT687180E (pt) * 1992-12-22 2001-04-30 Ludwig Inst Cancer Res Metodos para a deteccao e o tratamento de individuos tendo celulas anormais que expressam antigenios do peptido hla-a2/tirosinase
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Also Published As

Publication number Publication date
US8153138B2 (en) 2012-04-10
EP0836648B1 (en) 2003-05-07
DE69628011D1 (de) 2003-06-12
CZ292460B6 (cs) 2003-09-17
EE05138B1 (et) 2009-02-16
IL202448A0 (en) 2011-07-31
ES2249648T3 (es) 2006-04-01
PT836648E (pt) 2003-09-30
DK1312678T3 (da) 2005-12-19
US20100291139A1 (en) 2010-11-18
JP4764366B2 (ja) 2011-08-31
US20030035792A1 (en) 2003-02-20
CA2596274C (en) 2010-09-07
NO322476B1 (no) 2006-10-09
IL164318A0 (en) 2005-12-18
EE200300332A (et) 2003-10-15
EE04753B1 (et) 2006-12-15
UA75411C2 (en) 2006-04-17
IL164318A (en) 2013-08-29
KR19990028617A (ko) 1999-04-15
ES2199294T3 (es) 2004-02-16
EP0836648A1 (en) 1998-04-22
HU224061B1 (hu) 2005-05-30
TWI245075B (en) 2005-12-11
EE9700344A (et) 1998-06-15
DE69635173D1 (de) 2005-10-13
ATE239796T1 (de) 2003-05-15
WO1997002355A1 (en) 1997-01-23
CA2225278C (en) 2009-01-27
HUP9802217A3 (en) 1999-09-28
EP1312678A1 (en) 2003-05-21
EP1312678B1 (en) 2005-09-07
NO980026D0 (no) 1998-01-02
CZ424197A3 (cs) 1998-03-18
US6440422B1 (en) 2002-08-27
CA2596274A1 (en) 1997-01-23
SI1312678T1 (sl) 2006-02-28
NO980026L (no) 1998-01-02
JPH11509091A (ja) 1999-08-17
EE04199B1 (et) 2003-12-15
TW200305646A (en) 2003-11-01
IL212933A0 (en) 2011-07-31
DE69635173T2 (de) 2006-07-13
CA2608864A1 (en) 1997-01-23
US8197825B2 (en) 2012-06-12
SI0836648T1 (en) 2003-12-31
UA75410C2 (en) 2006-04-17
NZ313597A (en) 1999-01-28
IL122120A0 (en) 1998-04-05
HK1068015A1 (en) 2005-04-22
AU6611096A (en) 1997-02-05
BR9609303B1 (pt) 2014-04-08
UA68327C2 (en) 2004-08-16
US20070071770A1 (en) 2007-03-29
US20070071769A1 (en) 2007-03-29
DE69635172D1 (de) 2005-10-13
IL122120A (en) 2005-07-25
ATE304057T1 (de) 2005-09-15
BR9609303B8 (pt) 2014-05-06
EP1312679A1 (en) 2003-05-21
DE69635172T2 (de) 2006-06-22
AU721735B2 (en) 2000-07-13
SI1312679T1 (sl) 2006-02-28
MX9800025A (es) 1998-03-31
PL186857B1 (pl) 2004-03-31
CA2608864C (en) 2010-09-07
HU229261B1 (en) 2013-10-28
ATE304058T1 (de) 2005-09-15
HK1009830A1 (en) 1999-06-11
DK1312679T3 (da) 2006-01-09
EP1312679B1 (en) 2005-09-07
US7198934B2 (en) 2007-04-03
DE69628011T2 (de) 2004-03-18
EP1312679B8 (en) 2005-11-23
HU0402350D0 (en) 2005-01-28
JP2007244382A (ja) 2007-09-27
ES2249647T3 (es) 2006-04-01
TW575664B (en) 2004-02-11
HUP9802217A2 (hu) 1999-01-28
CN1782071A (zh) 2006-06-07
PL324347A1 (en) 1998-05-25
DK0836648T3 (da) 2003-08-25
CA2225278A1 (en) 1997-01-23
RU2198217C2 (ru) 2003-02-10
JP4764367B2 (ja) 2011-08-31
BR9609303A (pt) 1999-05-25
CN1189857A (zh) 1998-08-05
CN1554764A (zh) 2004-12-15
US20100266630A1 (en) 2010-10-21
JP2007252374A (ja) 2007-10-04
IL219528A0 (en) 2012-06-28
JP4312260B2 (ja) 2009-08-12
CN1554764B (zh) 2012-03-21
CN1154742C (zh) 2004-06-23

Similar Documents

Publication Publication Date Title
EE200300331A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
DE69332831D1 (de) Rekombinanter schweinepocken-virus
RU98101904A (ru) Рекомбинантный вирус mva и его использование
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
MY119381A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231